For the first time, all four Dengue virus (DENV) NS1 serotypes from human cell lines are now commercially available from Native Antigen Co, United Kingdom. The DENV NS1 serotypes have been manufactured in response to the unmet need for highly purified, concentrated proteins for use in vaccine development and serological-based diagnostic assays. NAC has used its novel platform based on human cell lines to focus on NS1’s hexameric presentation, which is the biologically active form of NS1 involved in key aspects of dengue pathogenesis. The resultant DENV NS1 proteins are then purified to a high degree, left in their native folding state, and possess all post-translational modifications. Dengue infection is a leading cause of illness and death in the tropics and subtropics, with as many as 100 million people infected annually. No vaccine is currently available. For more information, visit the Native Antigen Co.
